Happy Holidays from Innovation Partners! We hope everyone has a lovely holiday and a Happy New Year. We’re heading into an election year, and that means that several bills on Capitol Hill may be stalled until after November. Lobbyists continue to meet with lawmakers about Nancy Pelosi’s drug pricing bill, predicting it will squelch innovation ...

This week, cancer treatment and care are in the spotlight in the Innovation Partners BioBlog. Treatment for AML and new drugs to target various cancers are in the news in addition to the price transparency rule and findings related to Medicare charges. Read on for more in this week's Innovation Partners BioBlog. Hospitals sue CMS ...

This week's Innovation Partners BioBlog focuses on moves that drug companies are making both here and abroad. Canada pushed back at President Trump's plans to import drugs from Canada. Novartis plans to open a gene cell therapy manufacturing plant in Stein, Switzerland, to eliminate costly and time-consuming transatlantic flights of its medications from New Jersey ...

The pushback continues against the impending enactment in 2020 of a tax on medical devices, part of the Affordable Care Act legislation that's been delayed for ten years. Humana reports favorable results with its Medicare Advantage plans and provides evidence that it both saves money and improves outcomes. UnitedHealthcare will open MA centers in Walgreens ...

This week’s Innovation Partners BioBlog examines two emerging trends: fewer people enrolling in the Affordable Care Act and more people choosing $0 premiums during Medicare enrollment. President Trump continues to push to mandate low drug prices while the drug makers push back. These and more are the top stories in this week’s Innovation Partners BioBlog. ...

This week, the Innovation Partners BioBlog looks are breaking articles on how technology can help the shift to new healthcare payment models. Voters agree that the soaring cost of drug prices should be curbed, but disagree on how to do so. CMS delayed its ruling to hospitals and healthcare providers to post their prices, stating ...

In this week’s Innovation Partners BioBlog, we look at top stories impacting the world of healthcare especially those affected by politics and legislation. Senator Pelosi pushes for passage of her bill to lower drug prices but opponents believe it will stifle innovation and the development of new drugs. The Trump Administration delayed the start of ...

In this week’s Innovation Partners BioBlog, we look at several top stories from the pharmaceutical industry. Merck is testing machine learning to predict demand, a move that is expected to prevent wasteful stockpiling and expired drugs. Pfizer fills the gap left by Teva’s discontinuation of an important cancer-fighting drug often used for children’s cancers. Several ...

California Governor Newsom inked bill AB 824 and is expected to sign AB 744 this week, both of which will impact healthcare payment models. Companies seeking to manage healthcare costs are actively trying to influence where medications are delivered. New cancer research in triple negative breast cancer appears promising. Read on for these and other ...

The European Society of Medical Oncology (ESMO) conference wrapped up this week with many exciting announcements and developments. New studies from Lilly, AstraZeneca, Merck and others showed promise treating lung cancer, thyroid cancer, prostate cancer and more. Hospitals and medical groups are pushing back at the Trump administration’s focus on publishing payer-negotiated pricing. Read on ...